This study is designed as a dose escalation study to assist with the exploration of safety and finding the most effective dose in this population. Subjects assigned to the MDMA group will receive two of three different doses, either 75mg, 100mg, or 125 mg MDMA. Overall, eight subjects (66.7%) will be randomized to the MDMA group and four subjects (33.3%) will be randomized to the placebo group. During the study, there will be a maximum of 24 experimental sessions with MDMA, with eight sessions in each dose group, and eight experimental sessions with placebo. Observations before, during, and after experimental sessions will be compared between these groups of equal size to explore the effects of MDMA-assisted therapy in the first double